

## Special Issue

# Targeted Drug Delivery to Brain

### Message from the Guest Editor

The poor transport of therapeutics across various central nervous system barriers is a primary clinical challenge in the development of treatments for brain diseases. As a result, the majority of drugs for neurological diseases need to be administered at high doses, leading to systemic side effects and toxicities. Recent developments in the area of targeted brain-delivery strategies using nanotechnology, gene-therapy and cell-based therapeutics have shown significant promise for enhancing the efficacy and safety of drugs by specifically delivering them to targeted locations in the brain. This Special Issue of *Biomedicines* focuses on the recent advancements in the field of brain drug and gene-delivery strategies aiming for delivery to specific regions, cells, and sub-cellular locations within the brain for the treatment of unmet clinical needs in the area of neurological diseases. We invite original research and review articles focusing on the challenges associated with drug delivery across the brain and the development of nanoparticles or biologics-based brain-targeted platforms for drug-/gene-delivery, imaging, and diagnostic applications.

### Guest Editor

Dr. Anjali Sharma

Department of Chemistry, Washington State University, Pullman, WA 99164-4630, USA

### Deadline for manuscript submissions

closed (31 July 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/99167](https://mdpi.com/si/99167)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).